Richard A. Larson to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Richard A. Larson has written about Randomized Controlled Trials as Topic.
Connection Strength
0.368
-
Is there a best TKI for chronic phase CML? Hematology Am Soc Hematol Educ Program. 2015; 2015:250-6.
Score: 0.093
-
Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in CML. Clin Adv Hematol Oncol. 2009 Feb; 7(2):S3-5.
Score: 0.062
-
End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood. 2007 Mar 01; 109(5):1810-6.
Score: 0.053
-
Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial. Future Oncol. 2022 Dec; 18(38):4161-4170.
Score: 0.040
-
Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B. Hematol Oncol Clin North Am. 2000 Dec; 14(6):1367-79, x.
Score: 0.035
-
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013 Aug 08; 122(6):872-84.
Score: 0.021
-
Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies. J Clin Oncol. 2013 Feb 01; 31(4):440-7.
Score: 0.020
-
Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood. 2011 Jun 30; 117(26):7007-13.
Score: 0.018
-
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006 Aug 20; 24(24):3895-903.
Score: 0.013
-
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol. 2006 Jan 20; 24(3):437-43.
Score: 0.012